193 related articles for article (PubMed ID: 22718190)
1. Autosomal dominant polycystic kidney disease is associated with central and nephrogenic defects in osmoregulation.
Ho TA; Godefroid N; Gruzon D; Haymann JP; Maréchal C; Wang X; Serra A; Pirson Y; Devuyst O
Kidney Int; 2012 Nov; 82(10):1121-9. PubMed ID: 22718190
[TBL] [Abstract][Full Text] [Related]
2. Vasopressin, copeptin, and renal concentrating capacity in patients with autosomal dominant polycystic kidney disease without renal impairment.
Zittema D; Boertien WE; van Beek AP; Dullaart RP; Franssen CF; de Jong PE; Meijer E; Gansevoort RT
Clin J Am Soc Nephrol; 2012 Jun; 7(6):906-13. PubMed ID: 22516290
[TBL] [Abstract][Full Text] [Related]
3. Urine and plasma osmolality in patients with autosomal dominant polycystic kidney disease: reliable indicators of vasopressin activity and disease prognosis?
Casteleijn NF; Zittema D; Bakker SJ; Boertien WE; Gaillard CA; Meijer E; Spithoven EM; Struck J; Gansevoort RT
Am J Nephrol; 2015; 41(3):248-56. PubMed ID: 25926129
[TBL] [Abstract][Full Text] [Related]
4. Urine Concentrating Capacity, Vasopressin and Copeptin in ADPKD and IgA Nephropathy Patients with Renal Impairment.
Zittema D; Casteleijn NF; Bakker SJ; Boesten LS; Duit AA; Franssen CF; Gaillard CA; Gansevoort RT
PLoS One; 2017; 12(1):e0169263. PubMed ID: 28081165
[TBL] [Abstract][Full Text] [Related]
5. Urine concentration ability is reduced to the same degree in adult dominant polycystic kidney disease compared with other chronic kidney diseases in the same CKD-stage and lower THAN in healthy control subjects - a CASE control study.
Malmberg MH; Mose FH; Pedersen EB; Bech JN
BMC Nephrol; 2020 Aug; 21(1):379. PubMed ID: 32867720
[TBL] [Abstract][Full Text] [Related]
6. Osmoregulation, vasopressin, and cAMP signaling in autosomal dominant polycystic kidney disease.
Devuyst O; Torres VE
Curr Opin Nephrol Hypertens; 2013 Jul; 22(4):459-70. PubMed ID: 23736843
[TBL] [Abstract][Full Text] [Related]
7. A defect in vasopressin secretion in autosomal dominant polycystic kidney disease.
Bichet DG
Kidney Int; 2012 Nov; 82(10):1051-3. PubMed ID: 23128116
[TBL] [Abstract][Full Text] [Related]
8. Short-term Effects of Tolvaptan in Individuals With Autosomal Dominant Polycystic Kidney Disease at Various Levels of Kidney Function.
Boertien WE; Meijer E; de Jong PE; ter Horst GJ; Renken RJ; van der Jagt EJ; Kappert P; Ouyang J; Engels GE; van Oeveren W; Struck J; Czerwiec FS; Oberdhan D; Krasa HB; Gansevoort RT
Am J Kidney Dis; 2015 Jun; 65(6):833-41. PubMed ID: 25600953
[TBL] [Abstract][Full Text] [Related]
9. Bully renal cysts knock down urine-concentrating capacity in the early rounds.
Grantham JJ
Clin J Am Soc Nephrol; 2012 Jun; 7(6):875-7. PubMed ID: 22580782
[No Abstract] [Full Text] [Related]
10. Use of the Urine-to-Plasma Urea Ratio to Predict ADPKD Progression.
Heida JE; Gansevoort RT; Messchendorp AL; Meijer E; Casteleijn NF; Boertien WE; Zittema D;
Clin J Am Soc Nephrol; 2021 Feb; 16(2):204-212. PubMed ID: 33504546
[TBL] [Abstract][Full Text] [Related]
11. Copeptin, a surrogate marker for vasopressin, is associated with kidney function decline in subjects with autosomal dominant polycystic kidney disease.
Boertien WE; Meijer E; Zittema D; van Dijk MA; Rabelink TJ; Breuning MH; Struck J; Bakker SJ; Peters DJ; de Jong PE; Gansevoort RT
Nephrol Dial Transplant; 2012 Nov; 27(11):4131-7. PubMed ID: 22523115
[TBL] [Abstract][Full Text] [Related]
12. Low-Osmolar Diet and Adjusted Water Intake for Vasopressin Reduction in Autosomal Dominant Polycystic Kidney Disease: A Pilot Randomized Controlled Trial.
Amro OW; Paulus JK; Noubary F; Perrone RD
Am J Kidney Dis; 2016 Dec; 68(6):882-891. PubMed ID: 27663039
[TBL] [Abstract][Full Text] [Related]
13. Relative Validity of a Beverage Frequency Questionnaire Used to Assess Fluid Intake in the Autosomal Dominant Polycystic Kidney Disease Population.
Mannix C; Rangan A; Wong A; Zhang J; Allman-Farinelli M; Rangan G
Nutrients; 2018 Aug; 10(8):. PubMed ID: 30096903
[TBL] [Abstract][Full Text] [Related]
14. Copeptin, a surrogate marker of vasopressin, is associated with disease severity in autosomal dominant polycystic kidney disease.
Meijer E; Bakker SJ; van der Jagt EJ; Navis G; de Jong PE; Struck J; Gansevoort RT
Clin J Am Soc Nephrol; 2011 Feb; 6(2):361-8. PubMed ID: 20930090
[TBL] [Abstract][Full Text] [Related]
15. Relationship of copeptin, a surrogate marker for arginine vasopressin, with change in total kidney volume and GFR decline in autosomal dominant polycystic kidney disease: results from the CRISP cohort.
Boertien WE; Meijer E; Li J; Bost JE; Struck J; Flessner MF; Gansevoort RT; Torres VE;
Am J Kidney Dis; 2013 Mar; 61(3):420-9. PubMed ID: 23089511
[TBL] [Abstract][Full Text] [Related]
16. [Blood pressure, functional and morphological study of kidneys in children with autosomal dominant polycystic kidney disease].
Seeman T; Vondrichová H; Strízová J; Sikut M; Janda J; Schärer K
Cas Lek Cesk; 1999 Mar; 138(6):178-84. PubMed ID: 10510532
[TBL] [Abstract][Full Text] [Related]
17. A pilot clinical study to evaluate changes in urine osmolality and urine cAMP in response to acute and chronic water loading in autosomal dominant polycystic kidney disease.
Barash I; Ponda MP; Goldfarb DS; Skolnik EY
Clin J Am Soc Nephrol; 2010 Apr; 5(4):693-7. PubMed ID: 20167686
[TBL] [Abstract][Full Text] [Related]
18. Apelin and copeptin: two opposite biomarkers associated with kidney function decline and cyst growth in autosomal dominant polycystic kidney disease.
Lacquaniti A; Chirico V; Lupica R; Buemi A; Loddo S; Caccamo C; Salis P; Bertani T; Buemi M
Peptides; 2013 Nov; 49():1-8. PubMed ID: 23973863
[TBL] [Abstract][Full Text] [Related]
19. Renal cyst growth is the main determinant for hypertension and concentrating deficit in Pkd1-deficient mice.
Fonseca JM; Bastos AP; Amaral AG; Sousa MF; Souza LE; Malheiros DM; Piontek K; Irigoyen MC; Watnick TJ; Onuchic LF
Kidney Int; 2014 May; 85(5):1137-50. PubMed ID: 24429399
[TBL] [Abstract][Full Text] [Related]
20. Urinary excretion of AQP2 and ENaC in autosomal dominant polycystic kidney disease during basal conditions and after a hypertonic saline infusion.
Graffe CC; Bech JN; Lauridsen TG; Pedersen EB
Am J Physiol Renal Physiol; 2012 Apr; 302(8):F917-27. PubMed ID: 22262484
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
